Biogen Idec New Ventures

Biogen Idec New Ventures operates as the corporate venture capital arm of Biogen, strategically investing in early-stage life science companies. It targets innovative science, technologies, and therapeutic modalities aligned with Biogen's core interests. This approach efficiently integrates external innovations, augmenting Biogen's internal research and development pipeline.

Established in 2004, the venture arm formed one year after the 2003 merger creating Biogen Idec from Biogen and IDEC Pharmaceuticals. This initiative reflected the parent company's strategic insight to leverage external innovation for future growth. The dedicated investment entity identifies promising, early-stage research to complement internal drug development.

Biogen Idec New Ventures supports emerging biotechnology firms with critical early-stage capital and strategic guidance. Its long-term vision focuses on accelerating discovery and development of novel therapies, especially for patients battling neurological and neurodegenerative diseases. The firm cultivates an innovation ecosystem, aiming for a continuous stream of potential breakthroughs.